Tower Research Capital (TRC)’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Tower Research Capital (TRC)’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,940	Closed	-$6K	–	7024
2022 Q1	$6K	Buy	+1,940	New	+$5.58K	﹤0.01%	5000
2021 Q4	–	Sell	-1,426	Closed	-$6K	–	6960
2021 Q3	$6K	Buy	+1,426	New	+$7.34K	﹤0.01%	4812
2021 Q2	–	Sell	-1,976	Closed	-$24K	–	6168
2021 Q1	$24K	Buy	1,976 +650	+49%	+$9.24K	﹤0.01%	3753
2020 Q4	$19K	Sell	1,326 -5,486	-81%	-$69.9K	﹤0.01%	3917
2020 Q3	$78K	Buy	+6,812	New	+$87.3K	﹤0.01%	3327

Tower Research Capital (TRC)'s CMPI Position: Q2 2022 in Review

Tower Research Capital (TRC) sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 1,940 shares — an estimated $6K sold.

Tower Research Capital (TRC) first reported a position in CMPI in Q3 2020 and held it in 5 quarters. The position peaked at $78K in Q3 2020. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Tower Research Capital (TRC) reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,940 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $6K.
Tower Research Capital (TRC) first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Tower Research Capital (TRC)'s Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $78K in Q3 2020.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.